Hormones Signaling and Myocardial Ischemia

Chapter
Part of the Basic Science for the Cardiologist book series (BASC, volume 21)

Abstract

Although hormones constitute an important component of the adaptive response of the living organism to various stresses, their role in myocardial ischemia has not been adequately explored. However, recent research reveals that hormone signaling is of physiological relevance in the context of ischemia and reperfusion. Furthermore, hormones or hormones’ analogs are suggested as potential therapeutic agents for treating heart diseases.

Keywords

Thyroid Hormone Infarct Size Thyroid Hormone Receptor Anabolic Androgenic Steroid Cardioprotective Role 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S.E. Anderson, D.M. Kirkland, A. Beyschau and P.M. Cala, Acute effects of beta—estradiol on myocardial pH, Na and Ca and ischemia and reperfusion, Am. J. Physiol. 288(1), C57–64 (2005)Google Scholar
  2. 2.
    E.R. Booth, M. Marchesi, E.J. Kilbourne and B.R. Lucchesi, 17β estradiol as a receptor-mediated cardioprotective agent, J. Pharmacol. Exper: Ther. 307, 395–401 (2003).Google Scholar
  3. 3.
    C.H. Tsai, S.F. Su, T.F. Chou and T.M. Lee, Differential effects of sarcolemmal and mitochondria1 K(ATP) channels activated by 17 beta estradiol on reperfusion arrhythmias and infarct sizes in canine hearts, J. Pharmacol. Exp. Ther. 301, 234–240 (2002).PubMedGoogle Scholar
  4. 4.
    K. Node, M. Kitakaze, H Kosaka, T. Minamino, H. Funaya and M. Hori, Amelioration of ischemia and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium activated potassium channels, Circulation 96(6), 1953–1963 (1997).PubMedGoogle Scholar
  5. 5.
    T.M. Lee, T.F. Chou and C.H. Tsai, Differential role of KATP, channels activated by conjugated estrogens in the regulation of myocardial and coronary protective effects, Circulation 107, 49–54 (2003).PubMedGoogle Scholar
  6. 6.
    S. Beer, M. Reincke, M. Kral, S.Z. Lie, S. Steinhauer, H.H. Schmidt, B. Allolio and S. Neubauer, Susceptibility to cardiac ischemia/reprfusion injury is modulated by chronic estrogen status, J. Cardiovasc. Pharmacol. 40, 420–428 (2002).PubMedGoogle Scholar
  7. 7.
    M. Grist, R.B. Wambolt, G.P. Bondy, D.R. English and M.F. Allard, Estrogen replacement stimulates fatty acid oxidation and impairs postischemic recovery of hearts from ovariectomized female rats, Can. J. Physiol. Pharmacol. 80, 1001–1007 (2002).PubMedGoogle Scholar
  8. 8.
    Y. Xu, S.J. Armstrong, I.A. Arenas, D.J. Pehowich, S.T. Davidge, Cardioprotection by chronic estrogen or superoxide dismutase mimetic treatment in the aged female rat, Am. J. Physiol. 287, H165–H171 (2004).Google Scholar
  9. 9.
    T. Shinohara, N. Takahashi, T. Ooie, M. Ishinose, M. Hara, H. Yonemoshi, T. Saikawa and H. Yoshimatsu, Estrogen inhibits hyperthermia —induced expression of heat shock protein 72 and cardioprotection against ischemia/reperfusion injury in female rat heart, J. Mol. Cell. Cardiol. 37, 1053–1061 (2004).PubMedGoogle Scholar
  10. 10.
    K.L. Hamilton, S. Gupta, A.A. Knowlton, Estrogen and regulation of heat shock protein expression in female cardiomyocytes: cross —talk with NFkB signaling, J. Mol. Cell. Cardiol. 36, 577–584 (2004)PubMedGoogle Scholar
  11. 11.
    P. Zhai, T.E. Eurell, P.S. Cooke, D.B. Lubahn and D.R. Gross, Myocardial ischemia and reperfusion injury in estrogen receptor-alpha knockout and wild-type mice, Am. J. Physiol. 278(5), H1640–H1647 (2000).Google Scholar
  12. 12.
    H. Ogita, K. Node, H. Asanuma, S. Sanada, Y. Liao, S. Takashima, M. Asakura, H. Mori, Y. Shinozaki, M. Hori and M. Kitakaze, Amelioration of ischemia and reperfusion induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart, J. Am. Coll. Cardiol. 40, 998–1005 (2002).PubMedGoogle Scholar
  13. 13.
    F. Er, G. Michels, N. Gassanov, F. Rivero and U.C. Hoppe, Testosterone induces cytoprotection by activating ATP-sensitive K+ channels in the cardiac mitochondria1 inner membrane, Circulation 110(19), 3100–3107 (2004).PubMedGoogle Scholar
  14. 14.
    F. Callies, H. Stromer, R. Schwinger, B. Bolck, K. Hu, S. Frantz, A. Leupold, S. Beer, B. Allolio and A.W. Bonz, Administration of testosterone is associated with a reduced susceptibility to myocardial ischemia, Endocrinology 144, 4478–4483 (2004).Google Scholar
  15. 15.
    M. Wang, B.M. Tsai, A. Kher, L.B. Baker, G.M. Wairiuko, D.R. Meldrum, The role of endogenous testosterone in myocardial proinflammatory and proapoptotic signaling after acute ischemia and reperfusion, Am. J. Physiol. 288(1), H221–226 (2005).Google Scholar
  16. 16.
    E.F. Du Toit, E. Rossouw, J. Van Rooyen and A. Lochner, Proposed mechanism for the anabolic steroid induced increase in myocardial susceptibility to ischemia/reperfusion injury, Cardiovasc. J. S. Afr. 16(1), 21–28 (2005).PubMedGoogle Scholar
  17. 17.
    V. De Gennaro Colonna, G. Rossoni, M. Bernareggi, E.E. Muller and F. Berti, Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin, Eur, J, Pharmacol. 334(2–3), 201–207 (1997).Google Scholar
  18. 18.
    G. Rossoni, V. De Gennaro Colonna, M. Bernareggi, G.L. Polvani, E.E. Muller and F. Berti, Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats, J. Cardiovasc. Pharmacol. 32(2), 260–265 (1998).PubMedGoogle Scholar
  19. 19.
    F. Weekers, E. van Herck, J. Isgaard and G. van den Berghe, Pretreatment with growth hormone releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood—perfused rabbit heart model, Endocrinology 141, 3993–3999 (2000).PubMedGoogle Scholar
  20. 20.
    S. Frascarelli, S. Ghelardoni, S. Ronca-Testoni and R. Zucchi, Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart, Basic Res. Cardiol. 98, 401–405 (2003).PubMedGoogle Scholar
  21. 21.
    L. Chang, Y. Ren, X. Liu W.G. Li, J. Yang, B. Geng, N.L. Weintraub and C. Tang, Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart, J. Cardiovasc. Phannacol. 43, 165–170 (2004).Google Scholar
  22. 22.
    G. Baldanzi, N. Filigheddu, S. Cutrupi, F. Catapano, S. Bonissoni, A. Fubini, D. Malan, G. Baj, R. Granata, F. Broglio, M. Papotti, N. Surico, F. Bussolino, J. Isgaard, R. Deghenghi, F. Sinigaglia, M. Prat, G. Muccioli, E. Ghigo and A. Graziani, Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI3-kinase/Akt, J. Cell. Biol. 159(6), 1029–1037 (2002).PubMedGoogle Scholar
  23. 23.
    A. Bourbon, M. Vionnet, P. Leprince, E. Vaissier, J Copeland, P. McDonagh, P. Debre and I. Gandjbakhch, The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response, Eur. J. Cardiothorac. Surg. 26(5), 932–938 (2004).PubMedGoogle Scholar
  24. 24.
    D.E. Sholter and P.W. Armstrong, Adverse effects of corticosteroids on the cardiovascular system, Can. J. Cardiol. 16(4), 505–511 (2000).PubMedGoogle Scholar
  25. 25.
    G. Valen, T. Kawakami, Tahepold, A. Dumitrescu, C. Lowbeer and J. Vaage, Clucocorticoid pretreatment protects cardiac function and induces cardiac heat shock protein 72, Am. J. Physiol. 279, H836–H843 (2000).Google Scholar
  26. 26.
    E. Varga, N. Nagy, J. Lazar, G. Czifra, I. Bak, T. Biro and A. Tosaki, Inhibition of ischemia/reperfusion—induced damage by dexamethasone in isolated working rat hearts: the role of cytochrome c release, Life Sci. 75, 2411–2423 (2004).PubMedGoogle Scholar
  27. 27.
    B.K. Brar, A.K. Jonassen, A. Stephanou, G. Santilli, J. Railson, R.A. Knight, D.M. Yellon and D.S. Latchman, Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway, J. Biol. Chem. 275(12), 8508–8514 (2000).PubMedGoogle Scholar
  28. 28.
    D.J. Hausenloy and D.M. Yellon, New directions for protecting the heart against ischemia and reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway, Cardiovasc. Res. 61, 448–460 (2004).PubMedGoogle Scholar
  29. 29.
    C. Bazzani, S. Guarini, A. Botticelli, D. Zaffe, A. Tomasi, A. Bini, M.C. Cainazzo, G. Ferrazza, C. Mioni and A. Bertolini, Protective effect of melanocortin peptides in rat myocardial ischemia. J. Pharmacol. Experimental. Therapeutics 297, 1082–1087 (2001).Google Scholar
  30. 30.
    R.J. Reiter and D.X. Tan, Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart, Cardiovasc. Res. 58, 10–19 (2003).PubMedGoogle Scholar
  31. 31.
    S. Kaneko, K. Okumura, Y. Numaguchi, H. Matsui, K. Murase, S. Mokuno, I. Morishima, K. Hira, Y. Toki, T. Ito and T. Hayakawa, Melatonin scavenges hydroxyl radical and protects isolated rat hearts from ischemic reperfusion injury, Life Sci. 67(2), 101–112 (2000).PubMedGoogle Scholar
  32. 32.
    E. Sahna, A. Acet, M.K. Ozer and E. Olmez, Myocardial ischemia and reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin, J. Pineal Res. 33(4), 234–238 (2002).PubMedGoogle Scholar
  33. 33.
    D.J. Duncker and P.D. Verdouw, Has melatonin a future as a cardioprotective agent? Cardiovasc. Drugs Thex 15, 205–207, (2001).Google Scholar
  34. 34.
    P. Van der Meer, E. Lipsic, R.H. Henning, R.A. de Boer, A.J.H. Suurmeijer, D.J. van Veldhuisen and W.H. van Gilst, Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia and reperfusion injury, Eur: J. Heart Fail. 6, 853–859 (2004).Google Scholar
  35. 35.
    A.F. Tramontano, R. Muniyappa, A.D. Black, M.C. Blendea, I. Cohen, L. Deng, J.R. Sowers, M.V. Cutaia and N. El-Sherif, Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway Biochem. Biophys. Res. Commun. 308, 990–994 (2003).PubMedGoogle Scholar
  36. 36.
    C.J. Parsa, A. Matsumoto, J. Kim, R.U. Reil, L.S. Pascal, G.B. Walton, R.B. Thompson, J.A. Petrofski, B.H. Annex, J.S. Stamler and W.J. Koch, A novel protective effect of erythropoietin in the infracted heart, J. Clin. Invest. 112, 999–1007 (2003).PubMedGoogle Scholar
  37. 37.
    G. Baxter, Natriuretic peptides and myocardial ischemia, Basic Res. Cardiol. 99, 90–93 (2004).PubMedGoogle Scholar
  38. 38.
    S.P. D’souza, M. Davis and G.F. Baxter, Autocrine and paracrine actions of natriuretic peptides in the heart, Pharmacol, Ther. 101(2), 113–129 (2004).Google Scholar
  39. 39.
    M.A. Rastegar, A. Vegh, J.G. Papp and J.R. Paratt, Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs, Cardiovasc. Drugs Ther 14(5), 471–479 (2000).PubMedGoogle Scholar
  40. 40.
    A. Halapas, R. Tenta, C. Pantos, D.V. Cokkinos and M. Koutsilieris, Parathyroid hormone-related peptide and cardiovascular system, Vivo 17(5), 425–32 (2003).Google Scholar
  41. 41.
    K.L. Laugwitz, H.J. Weig, A. Moretti, E. Hoffmann, P. Ueblacker, I. Pragst, K. Rosport, A. Schomig and M. Ungerer, Gene transfer of heterologous G protein-coupled receptors to cardiomyocytes: differential effects on contractility, Circ Res. 88(7), 688–95 (2001).PubMedGoogle Scholar
  42. 42.
    K.D. Schluter, M. Weber and H.M. Piper, Effects of PTH-rP(107–11 I) and PTH-rP(7–34) on adult cardiomyocytes, J. Mol. Cell. Cardiol. 29(11), 3057–65 (1997).PubMedGoogle Scholar
  43. 43.
    K. Schluter, C. Katzer, K. Frischkopf, S. Wenzel, G. Taimor and H.M. Piper, Expression, release, and biological activity of parathyroid hormone-related peptide from coronary endothelial cells, Circ Res. 86(9), 946–51 (2000).PubMedGoogle Scholar
  44. 44.
    J. Jansen, P. Gres, C. Umschlag, F.R. Heinzel, H. Degenhardt, K.D. Schluter, G. Heusch and R. Schulz, Parathyroid hormonerelated peptide improves contractile function of stunned myocardium in rats and pigs, Am. J. Physiol. 284, H49–H55 (2003).Google Scholar
  45. 45.
    A. Rochetaing, C. Chapon, L. Marescaux, A. Le Boui1, A. Furber, P. Kreher. Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats, Can. J. Physiol. Pharmacol. 81, 864–872 (2003).PubMedGoogle Scholar
  46. 46.
    D.M. Purdham, M.X. Zou, V. Rajapurohitam and M. Karmazyn, Rat heart is a site of leptin production and action. Am. J. Physiol. Heart 287(6), H2877–84 (2004).Google Scholar
  47. 47.
    M.W. Nickola, L.E. Wold, P.B. Colligan, G.J. Wang, W.K. Samson and J. Ren, Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO, Hypertension 36(4), 501–5 (2000).PubMedGoogle Scholar
  48. 48.
    V. Rajapurohitam, X.T. Gan, L.A. Kirshenbaum and M. Karmazyn, The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes, Circ Res. 93(4), 277–279 (2003).PubMedGoogle Scholar
  49. 49.
    L.L. Atkinson, M.A. Fischer and G.D. Lopaschuk, Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis, J. Biol. Chem. 277(33), 29424–29430 (2002).PubMedGoogle Scholar
  50. 50.
    S.R. Meisel, M. Ellis, C. Pariente, H. Paumer, M. Liebowitz, D. David and I. Shimon, Serum leptin levels increase following acute myocardial infarction, Cardiology 95(4), 206–11 (2001).PubMedGoogle Scholar
  51. 51.
    E.D. Abel, Insulin signaling in heart muscle: lessons from genetically engineered mouse models, Curr. Hypertens. Rep. 6, 416–423 (2004).PubMedGoogle Scholar
  52. 52.
    L. Hue, C. Beauloye, A.S. Marsin, L. Bertrand, S. Horman and M.H. Rider, Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways, J. Mol. Cell Cardiol. 34, 109I–1097 (2002).Google Scholar
  53. 53.
    J. Deprez, L. Bertrand, D.R. Alessi, U. Krause, L. Hue and M.H. Rider, Partial purification and characterization of a wortmannin-sensitive and insulin-stimulated protein kinase that activates heart 6-phos-phofructo-2-kinase, Biochem. J. 347, 305–312 (2000).PubMedGoogle Scholar
  54. 54.
    C. Beauloye, A.S. Marsin, L. Bertrand, U. Krause, D.G. Hardie, J.L. Vanoverschelde and L. Hue, Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides, FEBS Lett. 505(3), 348–352 (2001).PubMedGoogle Scholar
  55. 55.
    C. Beauloye, L. Bertrand, U. Krause, A.S. Marsin, T. Dresselaers, F. Vanstapel, Vanoverschelde and L. Hue, No-flow ischemia inhibits insulin signalling in heart by decreasing intracellular pH, Circ. Res. 88(5), 513–519 (2001).PubMedGoogle Scholar
  56. 56.
    A.K. Jonassen, M.N. Sack, O.D. Mjos and D.M. Yellon, Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ. Res. 89, 1191–1198 (2001).PubMedGoogle Scholar
  57. 57.
    F. Gao, E. Gao, T.L. Yue, E.H. Ohlstein, B.L. Lopez, T.A. Christopher and X.L. Ma, Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia and reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation, Circulation 105(12), 1497–502 (2002).PubMedGoogle Scholar
  58. 58.
    F. Fath-Ordoubadi and K.J. Beatt, Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials, Circulation 96(4), 1152–1156 (1997).PubMedGoogle Scholar
  59. 59.
    S. Gradinac, G.M. Coleman, H. Taegtmeyer, M.S. Sweeney and O.H. Frazier, Improved cardiac function with glucose-insulin-potassium after aortocoronary bypass grafting, Ann. Thorac. Surg. 48(4), 484–489 (1989).PubMedGoogle Scholar
  60. 60.
    M.N. Sack and D. Yellon, Insulin therapy as an adjunct to reperfusion after acute coronary ischemia, J. Am. Coll. Cardiol. 41, 1404–1407 (2003).PubMedGoogle Scholar
  61. 61.
    A.K. Jonassen, E. Aasum, R.A. Riemersma, O.D. Mjos and T.S. Larsen, Glucose—insulin—potassium reduces infarct size when administered during reperfusion, Cardiovasc. Drugs Thex 14, 615–623 (2000).Google Scholar
  62. 62.
    H.F. Zhang, Q. Fan, X.X. Qian, B.L. Lopez, T.A. Christopher, X.L. Ma and F. Gao, Role of insulin in the antiapoptotic effect of glucose—insulin—potassium in rabbits with acute myocardial ischemia and reperfusion. Apoptosis 9, 777–783 (2004).PubMedGoogle Scholar
  63. 63.
    A.K. Jonassen, B.K. bar, O.D. Mjos, M.N. Sack, D.S. Latchman and D.M. Yellon, Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism, J. Moll. Cel. Cardiol. 32(5), 757–764 (2000).Google Scholar
  64. 64.
    L.H. Opie, The glucose hypothesis: relation to acute myocardial ischemia, J. Mol. Cell Cardiol. 1, 107–114 (1970).Google Scholar
  65. 65.
    Y. Fujio, T. Nguyen, D. Wencker, R.N. Kitsis and K. Walsh, Akt promotes survival of cardiomyocytes in vitro and protects against ischemia and reperfusion injury in mouse heart, Circulation 101(6), 660–467 (2000).PubMedGoogle Scholar
  66. 66.
    M. Parrizas, A.R. Saltiel and D. LeRoith, Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138(3), 1355–1358 (1997).PubMedGoogle Scholar
  67. 67.
    K. Yamashita, J. Kajstura, D.J. Discher, B.J. Wasserlauf, N.H. Bishopric, P. Anversa and K.A. Webster, Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1, Circ. Res. 88, 609–614 (2001).PubMedGoogle Scholar
  68. 68.
    D.P. Kelly and R.C. Scarpulla, Transcriptional regulatory circuits controlling mitochondria1 biogenesis and function, Genes Dev. 18, 357–368 (2004).PubMedGoogle Scholar
  69. 69.
    N.S. Wayman, Y. Hattori, M.C. Mc Donald, H. Mota-Filipe, S. Cuzzocrea, B. Pisano, P.K. Chatterjee and C. Thiemermann, Ligands of the peroxisome proliferator activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size, FASEB J. 16, 1027–1040 (2002).PubMedGoogle Scholar
  70. 70.
    H.R. Liu, L. Tao, E. Gao, B.L. Lopez, T.A. Christopher, R.N. Willette, E.H. Ohlstein, T.L. Yue and X.L. Ma, Antiapoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischaemia and reperfusion, Cardiovasc. Res. 62, 135–144 (2004).PubMedGoogle Scholar
  71. 71.
    Y. Xu, M. Gen, J. Fox, S.O. Weiss, R.D. Brown, D. Perlov, H. Ahmad, P. Zhu, C. Greyson, C.S. Long and G.G. Schwartz, PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs, Am. J. Physiol. 288(30), H1314–H1323, 2005.Google Scholar
  72. 72.
    M.E. Young, F.A. Laws, G.W. Goodwin and H. Taegtmeyer, Reactivation of PPAR-alpha is associated with contractile dysfunction in hypertrophied rat heart, Biol. Chem. 276(48), 44390–44395 (2001).Google Scholar
  73. 73.
    C. Pantos, V. Malliopoulou, D. Varonos and D.V. Cokkinos, Thyroid hormone and phenotypes of cardioprotection, Basic Res. Cardiol. 99, 101–120 (2004).PubMedGoogle Scholar
  74. 74.
    Q. Liu, A.S. Clanachan and G.D. Lopaschuk, Acute effects of hi-iodothyronine on glucose and fatty acid metabolism during reperfusion of ischemic rat hearts, Am. J. Physiol. 275(3), E392–399 (1998).PubMedGoogle Scholar
  75. 75.
    P.T. Buser, J. Wikman-Coffelt, S.T. Wu, N. Derugin, W.W. Parmley and C.B. Higgins, Postischemic recovery of mechanical performance and energy metabolism in the presence of left ventricular hypertrophy. A 31P-MRS study, Circ. Res. 66(3), 735–746 (1990).PubMedGoogle Scholar
  76. 76.
    C. Pantos, V. Malliopoulou, I. Mourouzis, E. Karamanoli, S.M. Tzeis, H. Carageorgiou, D. Varonos and D.V. Cokkinos, Long-term thyroxine administration increases Hsp70 mRNA expression and attenuates p38 MAP kinase activity in response to ischemia, J. Endocrinol. 170, 207–215 (2001).PubMedGoogle Scholar
  77. 77.
    C. Pantos, D.D. Cokkinos, S. Tzeis, V. Malliopoulou, I. Mourouzis, H. Carageorgiou, C. Limas, D. Varonos and D.V. Cokkinos, Hyperthyroidism is associated with preserved preconditioning capacity but intensified and accelerated ischemic contracture in rat heart, Basic Res. Cardiol. 94, 254–260 (1999).PubMedGoogle Scholar
  78. 78.
    K.G. Kolocassides, M. Galinanes and D.J. Hearse, Dichotomy of ischemic preconditioning. Improved postischemic contractile function despite intensification of ischemic contracture, Circulation 93, 1725–1733 (1996).PubMedGoogle Scholar
  79. 79.
    T. Asahi, M. Shimabukuro, Y. Oshiro, H. Yoshida and N. Takasu, Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats, Thyroid 11(11), 1009–1015 (2001).PubMedGoogle Scholar
  80. 80.
    J.A. Lahorra, D.F. Torchiana, C. Hahn, C.A. Bashour, A.G. Denenberg, J.S. Titus, W.M. Daggett and G.A. Geffin, Recovery after cardioplegia in the hypertrophic rat heart, J. Surg. Res. 88(2), 88–96 (2000)PubMedGoogle Scholar
  81. 81.
    P. Venditti, C. Agnisola and S. Di Meo, Effect of ischemia and reperfusion on heart mitochondria from hyperthyroid rats, Cardiovasc. Res. 56(1), 76–85 (2002).PubMedGoogle Scholar
  82. 82.
    C.M. Dyke, T. Yeh Jr, J.D. Lehman, A. Abd-Elfattah, M. Ding, A.S. Wechsler and D.R. Salter, Tri-iodothyronine-enhanced left ventricular function after ischemic injury, Ann. Thorac. Surg. 52(1), 14–19 (1991).PubMedGoogle Scholar
  83. 83.
    F.W. Holland 2nd, P.S. Brown Jr and R.E. Clark, Acute severe postischemic myocardial depression reversed by tri-iodothyronine, Ann. Thorac. Surg. 54(2), 301–305 (1992).PubMedGoogle Scholar
  84. 84.
    M. Kadletz, P.G. Mullen, M. Ding, L.G. Wolfe and AS. Wechsler, Effect of tri-iodothyronine on postischemic myocardial function in the isolated heart, Ann. Thorac. Surg. 57(3), 657–662 (1994).PubMedGoogle Scholar
  85. 85.
    C.M. Dyke, M. Ding, A.S. Abd-Elfattah, K. Loesser, R.J. Dignan, A.S. Wechsler and D.R. Salter, Effects of tri-iodothyronine supplementation after myocardial ischemia, Ann. Thorac. Surg. 56(2), 215–222 (1993).PubMedGoogle Scholar
  86. 86.
    D. Novitzky, N. Matthews, D. Shawley, D.K. Cooper and N. Zuhdi, Tri-iodothyronine in the recovery of stunned myocardium in dogs, Ann. Thorac. Surg. 51(1), 10–16 (1991).PubMedGoogle Scholar
  87. 87.
    J.D. Klemperer, I. Klein, M. Gomez, R.E. Helm, K. Ojamaa, S.J. Thomas, O.W. Isom and K. Krieger, Thyroid hormone treatment after coronary-artery bypass surgery, N Engl. J. Med. 333(23), 1522–1527 (1995).PubMedGoogle Scholar
  88. 88.
    D. Novitzky, D.K. Cooper and A. Swanepoel, Inotropic effect of tri-iodothyronine (T3) in low cardiac output following cardioplegic arrest and cardiopulmonary bypass: an initial experience in patients undergoing open heart surgery, Eur. J. Cardiothorac. Surg. 3(2), 140–145 (1989).PubMedGoogle Scholar
  89. 89.
    K. Ojamaa, A. Kenessey, R. Shenoy and I. Klein, Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat, Am. J. Physiol. 279, E1319–E1324 (2000).Google Scholar
  90. 90.
    K.W. Mahaffey, T.E. Raya, G.D. Pennock, E. Morkin and S. Goldman, Left ventricular performance and remodeling in rabbits after myocardial infarction: effects of a thyroid hormone analogue, Circulation 91(3), 794–801 (1995).PubMedGoogle Scholar
  91. 91.
    A.T. Saurin, J.L. Martin, R.J. Heads, C. Foley, J.W. Mockridge, M.J. Wright, Y. Wang and M.S. Marber, The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes, FASEB J. 14(14), 2237–2246 (2000).PubMedGoogle Scholar
  92. 92.
    E.T. Maizels, C.A. Peters, M. Kline, R.E. Cutler and M. Shanmugam, Heat-shock protein—25/27 phosphorylation by the δ isoform of protein kinase C, Biochem. J. 332, 703–712 (1998)PubMedGoogle Scholar
  93. 93.
    C. Pantos, V. Malliopoulou, I. Mourouzis, E. Karamanoli, P. Moraitis, S. Tzeis, I. Paizis, H. Carageorgiou, D. Varonos and D.V. Cokkinos, Thyroxine pretreatment increases basal myocardial Hsp27 expression and accelerates translocation and phosphorylation of this protein upon ischemia, Eur. J. Pharmacol. 478, 53–60 (2003).PubMedGoogle Scholar
  94. 94.
    C. Pantos, V. Malliopoulou, I. Mourouzis, E. Karamanoli, I. Paizis, N. Steimberg, D. Varonos and D.V. Cokkinos, Long-term Thyroxine Administration Protects the Heart in a Similar Pattern as Ischemic Preconditioning, Thyroid 12, 325–329 (2002).PubMedGoogle Scholar
  95. 95.
    C. Pantos, V. Malliopoulou, I. Paizis, P. Moraitis, I. Mourouzis, S. Tzeis, E. Karamanoli, D.D. Cokkinos, H. Carageorgiou, D. Varonos and D.V. Cokkinos, Thyroid hormone and cardioprotection; study of p38 MAPK and JNKs during ischemia and at reperfusion in isolated rat heart, Mol. Cell Biochem. 242, 173–180 (2003).PubMedGoogle Scholar
  96. 96.
    E. Marais, S. Genade, R. Salie, B. Huisamen, S. Maritz, J.A. Moolman and A. Lochner, The temporal relationship between p38 MAPK and Hsp27 activation in ischemic and pharmacological preconditioning, Basic Res. Cardiol. 100(1), 35–47 (2005).PubMedGoogle Scholar
  97. 97.
    C. Pantos, V. Malliopoulou, I. Mourouzis, K. Sfakianoudis, S. Tzeis, P. Doumha, C. Xinaris, A.D. Cokkinos, H. Carageorgiou, D. Varonos and D.V. Cokkinos, Propylthiouracil induced hypothyroidism is associated with increased tolerance of the isolated rat heart to ischemia and reperfusion. J. Endocrinol. 178(3), 427–435 (2003).PubMedGoogle Scholar
  98. 98.
    M. Abe, H. Obata and H. Tanaka, Functional and metabolic responses to ischemia in the isolated perfused hypothyroid rat heart, Jpn. Circ. J. 56(7), 671–680 (1992).PubMedGoogle Scholar
  99. 99.
    L.S. Carter, R.A. Mueller, E.A. Norfleet, F.B. Payne and L.S. Saltzman, Hypothyroidism delays ischemia-induced contracture and adenine nucleotide depletion in rat myocardium, Circ. Res. 60(5), 649–652 (1987).PubMedGoogle Scholar
  100. 100.
    M. Eynan, T. Knubuvetz, U. Meiri, G. Navon, G. Gerstenblith, Z. Bromberg, Y. Hasin and M. Horowitz, Heat acclimation-induced elevated glycogen, glycolysis, and low thyroxine improve heart ischemic tolerance, J. Appl. Physiol. 93(6), 2095–2104 (2002).PubMedGoogle Scholar
  101. 101.
    L. Zhang, J.R. Parratt, G.H. Beastall, N.J. Pyne and B.L. Furman, Streptozotocin diabetes protects against arrhythmias in rat isolated hearts: role of hypothyroidism, Euc J. Pharmacol. 435(2–3), 269–276 (2002).Google Scholar
  102. 102.
    L. Friberg, S. Werner, G. Eggertsen and S. Ahnve, Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch. Intern. Med. 162(12), 1388–1394 (2002).PubMedGoogle Scholar
  103. 103.
    K. Kinugawa, K. Yonekura, R.C. Ribeiro, Y. Eto, T. Aoyagi, J.D. Baxter, S.A. Camacho, M.R. Bristow, C.S. Long and P.C. Simpson, Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy, Circ. Res. 89(7), 591–598 (2001).PubMedGoogle Scholar
  104. 104.
    C. Pantos, I. Mourouzis, T. Saranteas, I. Paizis, C. Xinaris, V. Malliopoulou and D.V. Cokkinos, Thyroid hormone receptors α1 and β1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia-reperhion, Bas. Res. Cardiol. (2005), in press.Google Scholar
  105. 105.
    V. Drvota, M. Bronnegard, J. Hagglad, T. Barkhem and C. Sylven, Downregulation of thyroid hormone receptor subtype mRNA levels by amiodarone during catecholamine stress in vitro, Biochem. Biophys. Res. Commun. 211(3), 991–996 (1995).PubMedGoogle Scholar
  106. 106.
    0. Bakker, H.C. van Beeren and W.M. Wiersinga, Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone beta 1-receptor protein, Endocrinology 134(4), 1665–1670 (1994).PubMedGoogle Scholar
  107. 107.
    H.C. Van Beeren, O. Bakker and W.M. Wiersinga, Desethylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone alpha 1-receptor protein, Mol. Cell Endocrinol. 112(1), 15–19 (1995).PubMedGoogle Scholar
  108. 108.
    H.C. Van Beeren, W.M. Jong, E. Kaptein, T.J. Visser, O. Bakker and W.M. Wiersinga, Dronerarone acts as a selective inhibitor of 3,5,3’-tri-iodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. Endocrinology 144(2), 552–558 (2003).PubMedGoogle Scholar
  109. 109.
    C. Pantos, I. Mourouzis, V. Malliopoulou, I. Paizis, S. Tzeis, P. Moraitis, K. Sfakianoudis, D. Varonos and D.V. Cokkinos, Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor αl, Thyroid 15, 16–23 (2005).PubMedGoogle Scholar
  110. 110.
    S.U. Trost, E. Swanson, B. Gloss, D.B. Wang-Iverson, H. Zhang, T. Volodarsky, G.J. Grover, J.D. Baxter, G. Chiellini, T.S. Scanlan and W.H. Dillmann, The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity, Endocrinology 141(9), 3057–3064 (2000).PubMedGoogle Scholar
  111. 111.
    C. Pantos, I. Mourouzis, I. Paizis, P. Moraitis, A.D. Cokkinos and D.V. Cokkinos, Blockade of thyroid hormone receptor alpha 1: a new strategy for body weight reduction? Obes. Rev. 6(1), P146 (2005).Google Scholar
  112. 112.
    J.D. Baxter, D.H. Dillman, B.L. West, R. Huber, J.D. Furlow, R.J. Fletterick, P. Webb, J.W. Apriletti and T.S. Scanlan, Selective modulation of thyroid hormone receptor action, J. Ster. Biochem. Mol. Biol. 76, 31–42 (2001).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Department of PharmacologyUniversity of AthensGoudi, AthensGreece
  2. 2.1st Cardiology DepartmentOnassis Cardiac Surgery CenterKallithea, AthensGreece

Personalised recommendations